CN112239732A - 副干酪乳杆菌及副干酪乳杆菌用于制备去除醣化终产物的组合物的用途 - Google Patents
副干酪乳杆菌及副干酪乳杆菌用于制备去除醣化终产物的组合物的用途 Download PDFInfo
- Publication number
- CN112239732A CN112239732A CN202010695387.2A CN202010695387A CN112239732A CN 112239732 A CN112239732 A CN 112239732A CN 202010695387 A CN202010695387 A CN 202010695387A CN 112239732 A CN112239732 A CN 112239732A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus paracasei
- tci708
- lactobacillus
- paracasei
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000186605 Lactobacillus paracasei Species 0.000 title claims abstract description 116
- 239000007795 chemical reaction product Substances 0.000 title claims abstract description 50
- 239000000203 mixture Substances 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims abstract description 6
- 244000005700 microbiome Species 0.000 claims abstract description 8
- 230000000968 intestinal effect Effects 0.000 claims description 11
- 230000002496 gastric effect Effects 0.000 claims description 9
- 239000003833 bile salt Substances 0.000 claims description 8
- 210000004211 gastric acid Anatomy 0.000 claims description 7
- 230000004083 survival effect Effects 0.000 claims description 6
- 235000013305 food Nutrition 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 238000004113 cell culture Methods 0.000 claims description 2
- 230000015784 hyperosmotic salinity response Effects 0.000 claims 1
- 230000008021 deposition Effects 0.000 abstract 1
- 230000013595 glycosylation Effects 0.000 description 19
- 238000006206 glycosylation reaction Methods 0.000 description 19
- 230000037303 wrinkles Effects 0.000 description 18
- 241000186660 Lactobacillus Species 0.000 description 17
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 17
- 229940039696 lactobacillus Drugs 0.000 description 17
- 239000000243 solution Substances 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 12
- 230000001580 bacterial effect Effects 0.000 description 10
- 239000002775 capsule Substances 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 102000008186 Collagen Human genes 0.000 description 8
- 108010035532 Collagen Proteins 0.000 description 8
- 229920001436 collagen Polymers 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 7
- 239000001103 potassium chloride Substances 0.000 description 7
- 235000011164 potassium chloride Nutrition 0.000 description 7
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 6
- 229930091371 Fructose Natural products 0.000 description 6
- 239000005715 Fructose Substances 0.000 description 6
- 241000218492 Lactobacillus crispatus Species 0.000 description 6
- 240000006024 Lactobacillus plantarum Species 0.000 description 6
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 6
- 229940072205 lactobacillus plantarum Drugs 0.000 description 6
- 108020001027 Ribosomal DNA Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 5
- 210000004051 gastric juice Anatomy 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000007665 sagging Methods 0.000 description 5
- 239000002689 soil Substances 0.000 description 5
- 230000035899 viability Effects 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000006872 mrs medium Substances 0.000 description 3
- 244000025361 Ficus carica Species 0.000 description 2
- 235000008730 Ficus carica Nutrition 0.000 description 2
- 108091023242 Internal transcribed spacer Proteins 0.000 description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 description 2
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 2
- 240000001929 Lactobacillus brevis Species 0.000 description 2
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 2
- 241001147746 Lactobacillus delbrueckii subsp. lactis Species 0.000 description 2
- 241000186604 Lactobacillus reuteri Species 0.000 description 2
- 240000000599 Lentinula edodes Species 0.000 description 2
- 235000001715 Lentinula edodes Nutrition 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 230000036252 glycation Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 239000010977 jade Substances 0.000 description 2
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 2
- 229940001882 lactobacillus reuteri Drugs 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 201000010251 cutis laxa Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 229940012969 lactobacillus fermentum Drugs 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/165—Paracasei
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Birds (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Cosmetics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供一种副干酪乳杆菌TCI708(Lactobacillus paracasei TCI708),且此副干酪乳杆菌TCI708保藏于德国微生物保藏中心(German Collection of Microorganisms and Cell Cultures,DSMZ)(保藏号为:DSM33482)。本发明更提供一种副干酪乳杆菌TCI708(Lactobacillus paracasei TCI708)用于制备去除醣化终产物的组合物的用途,其中副干酪乳杆菌TCI708保藏于德国微生物保藏中心(保藏号为:DSM33482)。
Description
技术领域
本发明涉及一种副干酪乳杆菌,特别是关于一种副干酪乳杆菌TCI708(Lactobacillus paracaseiTCI708)及其用于制备去除醣化终产物的组合物的用途。
背景技术
醣化终产物(Advanced glycation end products,AGEs)是糖与蛋白质相互聚合并经过不可逆反应后产生的不可还原的物质。
研究发现醣化终产物会改变及影响蛋白质的正常功能。举例来说,醣化终产物会与其他蛋白质连成大分子,从而降低蛋白质被代谢的机会。此外,醣化终产物也会使DNA产生移位现象,造成DNA损伤,从而影响DNA正常功能。
醣化终产物除了于人体内自行生成外,亦充斥于日常饮食中。除了影响肌肤外,醣化终产物会通过肠道吸收而影响人体全身器官。并且,在病理学及流行病学的研究亦指出醣化终产物可影响人体内的任何组织和器官。
研究发现,肌肤的胶原网络被醣化终产物破坏,从而导致肌肤老化现象发生(如皱纹、松弛、暗沉、干燥)。并且,醣化终产物更与白内障、动脉硬化、骨质疏松等疾病相关。
此外,醣化终产物更与代谢症候群相关。动物实验发现小鼠在高剂量醣化终产物下的高脂饮食6周后,体重会比一般高脂饮食组体重增加比例高出 19%。
发明内容
有鉴于此,本发明提供一种副干酪乳杆菌及其用于制备去除醣化终产物(Advanced Glycation End Products,AGEs)的组合物的用途。
在一些实施例中,一种副干酪乳杆菌TCI708(Lactobacillus paracaseiTCI708),且此副干酪乳杆菌TCI708保藏于DSMZ德国微生物保藏中心 (German Collectionof Microorganisms and Cell Cultures,DSMZ)(保藏号为:DSM33482)。
在一些实施例中,一种副干酪乳杆菌TCI708(Lactobacillus paracasei TCI708)用于制备去除醣化终产物的组合物的用途,其中副干酪乳杆菌 TCI708保藏于德国国家菌种保藏中心(保藏号为:DSM33482)。
综上所述,任一实施例的副干酪乳杆菌TCI708是保藏于DSMZ德国微生物保藏中心(保藏号为:DSM33482)。并且,副干酪乳杆菌TCI708具有耐胃酸胆盐的功能。因此,副干酪乳杆菌TCI708于胃模拟环境的存活率为95%,且于肠道模拟环境的存活率为99%。在一些实施例中,副干酪乳杆菌TCI708可用以去除醣化终产物。因此,在一些实施例中,副干酪乳杆菌TCI708可用于制备去除醣化终产物的组合物,且组合物为医药组合物或食品组合物。
附图说明
图1是副干酪乳杆菌TCI708于肠胃模拟环境中的存活力实验的结果图;
图2是副干酪乳杆菌TCI708及其他乳杆菌属菌株对于醣化终产物的去除率实验的结果图:
图3是实验组于第0周及第4周的血液中醣化终产物浓度的分析图;
图4是实验组于第0周及第4周的肌肤明亮度的分析图;
图5是实验组于第0周及第4周的肌肤松弛度的分析图;
图6是实验组于第0周及第4周的皱纹的分析图;
图7是实验组受试者于第0周的皱纹照片;以及
图8是实验组受试者于第4周的皱纹照片。
其中,附图标记:
WK-0:皱纹
WK-4:皱纹
生物材料的保藏
副干酪乳杆菌TCI708,于2020年3月27日提交到DSMZ德国微生物保藏中心保藏,保藏号为:DSM33482。
具体实施方式
以下结合附图和具体实施例对本发明进行详细描述,但不作为对本发明的限定。
副干酪乳杆菌TCI708(Lactobacillus paracasei TCI708),是分离自中国台湾玉山土(高山土壤)的乳酸杆菌属的菌株。副干酪乳杆菌TCI708以保藏号DSM33482保藏于DSMZ德国微生物保藏中心。并且,此副干酪乳杆菌TCI708具有去除醣化终产物(AdvancedGlycation End Products, AGEs)的功能。
副干酪乳杆菌TCI708为革兰氏阳性杆菌,可于厌氧环境下生长,为兼性厌氧乳酸菌。副干酪乳杆菌TCI708生长的温度为35℃至37℃。并且,可于酸碱值(pH值)为3至7的环境下生存。
在一些实施例中,副干酪乳杆菌TCI708具有耐胃酸胆盐的功能。举例来说,副干酪乳杆菌TCI708于胃模拟环境(pH值3-4)的存活率为95%,且于肠道模拟环境(pH值7)的存活率为99%。
因此,副干酪乳杆菌TCI708可在人体肠胃道环境定殖,从而降低人体内醣化终产物的累积。藉此,副干酪乳杆菌TCI708可用于改善受体肌肤状况。
有此可知,在一些实施例中,副干酪乳杆菌TCI708可用于制备去除醣化终产物的组合物。并且,组合物可以为医药组合物或食品组合物。
在一些实施例中,组合物可用于改善肌肤状况,如提高肌肤明亮度、减少肌肤松弛度及/或改善皱纹。
实验一:菌种鉴定
首先,将分离自中国台湾玉山土的分离菌株以乳酸菌的16S核醣体基因(16SrDNA)进行菌种鉴定。通过聚合酶连锁反应(PCR)得到此分离菌株的16S核醣体基因(16SrDNA)序列(即SEQID NO:1)。接着,将 SEQID NO:1序列以美国国家生物技术资讯中心(NCBI)网站与其他副干酪乳酸菌亚种(如,Lactobacillus paracasei AMVDUDB5、Lactobacillusparacasei strain Lp02、Lactobacillus paracasei strain NJ等)的16S核醣体基因(16SrDNA)进行序列比对后可知,此分离菌株的16SrDNA序列与副干酪乳杆菌(Lactobacillus paracasei)相似性在98.49%至98.86%(如表1所示)。因此,将此分离菌株命名为副干酪乳杆菌TCI708。
表1
副干酪乳酸菌亚种 | 相似度 |
Lactobacillus paracasei AMVDUDB5 | 98.86% |
Lactobacillus paracasei strain Lp02 | 98.59% |
Lactobacillus paracasei strain NJ | 98.49% |
Lactobacillus paracasei strain HBUAS54287 | 98.49% |
Lactobacillus paracasei strain SRCM103299 | 98.49% |
Lactobacillus paracasei strain HBUAS53332 | 98.49% |
实验二:耐胃酸胆盐试验
为进一步确认副干酪乳杆菌TCI70的于生物体消化道的酸碱耐受性,将副干酪乳杆菌TCI708以人工胃液(pH 3)及人工肠液(pH 7)进行测试。实验组为人工胃液实验组及人工肠液实验组,其中人工胃液为0.2摩尔浓度(M)氯化钾(KCL,型号Sigma-Aldrich P9333)且pH值为3。人工肠液为0.2M氯化钾(KCL,型号Sigma-Aldrich P9333)及0.3重量%的牛胆盐(购自DifcoTMOxgall,型号212820)且pH值为7。并且,以氯化钾缓冲液作为控制组,其中氯化钾缓冲液为0.2M氯化钾(KCL,型号Sigma- Aldrich P9333)且pH值为7。
首先,将副干酪乳杆菌TCI708冻菌取相对于培养基10体积%的菌量培养于乳酸菌MRS培养基(BD DifcoTMLactobacilli MRS Broth,型号 DF0881-17-5)中,并于37℃下培养16小时,以活化副干酪乳杆菌 TCI708。接着,取相对于待测溶液1体积%的活化后的副干酪乳杆菌 TCI708菌液分别接种至20毫升的三组待测溶液中,其中三组待测溶液分别为人工胃液、人工肠液及氯化钾缓冲液,且人工胃液、人工肠液为二组实验组,而氯化钾缓冲液则为控制组。接着,以转速50rpm于37℃下将实验组及控制组震荡培养3小时。将培养后的三组菌液取100微升(μL)的菌液涂盘,并于37℃下静置培养3天,并于3天后计数三组的活菌数。
请参阅图1。附图中副干酪乳杆菌TCI708的存活力为计数后的活菌数,并以logCFU/mL表示。其中,log CFU/mL代表每毫升菌液含有的菌落形成单位(CFU,colony-formingunit)并以对数(log)表示。由图1可知,控制组的副干酪乳杆菌TCI708的存活力为7.85logCFU/mL(附图数值四舍五入)、人工胃液实验组的副干酪乳杆菌TCI708的存活力为7.48logCFU/mL(附图数值四舍五入),以及人工肠液实验组的副干酪乳杆菌 TCI708的存活力为7.81log CFU/mL(附图数值四舍五入)。
由此可知,人工胃液实验组的活菌数相对于控制组为95%,且人工肠液实验组的活菌数相对于控制组为99%。换言之,副干酪乳杆菌TCI708可于胃模拟环境(pH值3-4)存活且存活率为95%。副干酪乳杆菌TCI708亦可于肠道模拟环境(pH值7)存活且存活率为99%。因此,副干酪乳杆菌 TCI708具有耐胃酸胆盐的功能。
实验三:去除醣化终产物试验
将副干酪乳杆菌TCI708与其他乳酸菌属菌株一并进行去除醣化终产物试验,从而测试副干酪乳杆菌TCI708的去除醣化终产物的能力。实验三测试的乳酸菌属菌株为自行分离并筛选如表2所示,其中表2的编号代表图2 中各乳酸菌属菌株。
表2
于此,表2的10株乳酸菌属菌株是各别分离自人体肠道、玉山土、能高瀑布、无花果、牛粪或香菇的各分离株。将各分离株分别以乳酸菌的16S 核醣体基因(16SrDNA)及酵母菌内转录间隔区(internal transcribed spacer, ITS)基因进行菌种鉴定是通过NCBI确定各分离株的菌种。
由鉴定结果可知,来自玉山土的二分离株分别为副干酪乳杆菌 (Lactobacillusparacasei,编号:TCI708)及胚芽乳杆菌(Lactobacillus plantarum,编号:L805)、来自人体肠道的二分离株分别为嗜酸性乳酸杆菌(Lactobacillus acidophilus,编号:L800)及洛德乳酸杆菌(Lactobacillus reuteri,编号:L802)、来自能高瀑布的分离株为乳酸乳球菌(Lactococcuslactis,编号:L807)、来自无花果的分离株为副干酪乳杆菌 (Lactobacillusparacasei,编号:L1044)、来自母乳的二分离株为卷曲乳酸杆菌(Lactobacilluscrispatus,编号:L1228、L1231)、来自牛粪的分离株为酵素乳酸杆菌(Lactobacillusfermentum,编号:L1265),以及来自香菇的分离株为清酒乳酸杆菌(Lactobacillus sakei,编号:L1391)。其中, TCI708的鉴定报告如实验一所述。其中L1044的16S核醣体基因(16SrDNA)序列(即SEQID NO:2),以NCBI网站进行分析,可知其 16SrDNA序列与其他副干酪乳杆菌(Lactobacillus paracasei)亚种的相似性为98.96%。
将表2的各乳酸菌属的菌株冻菌分别取相对于培养基10体积%于乳酸菌MRS培养基(BD DifcoTMLactobacilli MRS Broth,型号DF0881-17-5) 中并于37℃下培养16小时以活化各乳酸菌属的菌株。
分别取0.4毫升的将胶原蛋白溶液(Collagen溶液)及果糖溶液 (Fructose溶液)混合均匀并置于50℃反应24小时以产生醣化终产物,其中Collagen溶液是以200mM磷酸钠缓冲溶液(Sodium phosphate buffer,pH 7.4)配置含有0.06%迭氮化钠(NaN3)且胶原蛋白浓度为每1毫升胶原蛋白溶液中含有60毫克(即60mg/mL)的胶原蛋白而成的Collagen溶液,而Fructose溶液是以200mM磷酸钠缓冲溶液(Sodium phosphate buffer,pH 7.4)配置果糖浓度为1.5M果糖(D-fructose)的Fructose溶液。
并且,调整活化后的各乳酸菌属菌株的菌液中含有的菌量为吸光值 (OD600)为1后,再加入相对于各组菌液1体积%的上述醣化终产物以作为各乳酸菌属菌株的实验组。相对于各乳酸菌属菌株的实验组,于相同菌量 (OD600=1)的各乳酸菌属菌株的菌液中加入1%乳酸菌MRS培养基以作为对应于各实验组的控制组。
接着,将各实验组及各控制组于37℃下培养16小时,接着以转速 13000rpm离心1分钟,以分离各实验组及各控制组的菌体及上清液。接着,各组取0.1毫升的上清液至96孔黑盘中,以激发光360nm及放射光 460nm下测定各组萤光值。并依照下列公式换算醣化终产物去除率(AGEs 去除率)。
公式:AGEs去除率=(1-实验组萤光值/对应的控制组萤光值)X100%
请参阅图2。相对于其他乳酸菌属菌株,副干酪乳杆菌TCI708的醣化终产物去除率为14%,高于胚芽乳酸菌L805(Lactobacillus plantarum L805)及卷曲乳杆菌L1228(Lactobacillus crispatus)的醣化终产物去除率。其中,胚芽乳酸菌L805的醣化终产物去除率为3%,而卷曲乳杆菌 L1228的醣化终产物去除率为5%。
除了上述三株菌株(即图2编号TCI708、L805、L1228),其余乳酸菌属菌株的醣化终产物去除率为0%。换言之,除了副干酪乳杆菌TCI708、胚芽乳酸菌L805及卷曲乳杆菌L1228,表2中的其他乳酸杆菌属菌株并无去除醣化终产物的能力。
此外,同样作为副干酪乳杆菌菌株的副干酪乳杆菌L1044 (Lactobacillusparacasei L1044)的醣化终产物去除率为0%。换言之,副干酪乳杆菌L1044不具有去除醣化终产物的能力。
由此可知,副干酪乳杆菌TCI708相对于同样为副干酪乳杆菌菌种的副干酪乳杆菌L1044具有去除醣化终产物的能力,具有与习知菌株(如副干酪乳杆菌L1044)不同的微生物性质。
实验四:人体试验
为进一步确认副干酪乳杆菌TCI708对于人体的影响。以每颗胶囊含有 5X109CFU(即5x109CFU/cap)副干酪乳杆菌TCI708的活菌胶囊提供给受试者每日服用一颗(50毫克/日,指每日服用一颗重量为50毫克的胶囊),并服用4周。并于服用前及服用4周后进行血液中醣化终产物浓度(委托立人检验所检测)、肌肤明亮度、肌肤松弛程度、皱纹等测试项目。
受试者有7位,且为年龄为20-55岁的女性及男性。并且,每位受试者均喜爱吃高油脂、甜食和烧烤食物等高含量醣化终产物的食物。
测试结果以第0周及第4周的数值一起比较。第0周为测试前量测的数值,代表受试者所有人均未服用含有副干酪乳杆菌TCI708的活菌胶囊的生理状态。第4周为连续服用四周后量测的数值。
(一)血液中醣化终产物浓度
于第0周及第4周时以2号黄头管收集7位受试者的血液,并委托立人检验所鉴测血液中醣化终产物浓度,结果如图3所示。
请参阅图3。7位受试者于第0周时平均的血液中醣化终产物浓度为 1.34单位/毫升(unit/mL),且于第4周时平均的血液中醣化终产物浓度为 1.27单位/毫升。换言之,7位受试者血液中醣化终产物浓度下降0.07单位/ 毫升,相较于第0周时下降5%。
由此可知,服用含有副干酪乳杆菌TCI708的活菌胶囊有助于下降人体血液中的醣化终产物浓度。因此,副干酪乳杆菌TCI708具有去除醣化终产物的能力。
(二)肌肤状态
请参阅图4。将7位受试者于第0周测试到的肌肤明亮度的平均数值视为100%,且7位受试者于第4周测试到的肌肤明亮度的平均数值相较于第 0周的数值为111.9%。换言之,在连续服用4周的含有副干酪乳杆菌 TCI708的活菌胶囊后,7位受试者肌肤明亮度上升11.9%。
请参阅图5。将7位受试者于第0周测试到的肌肤松弛度的平均数值视为100%,且7位受试者于第4周测试到的肌肤松弛度的平均数值相较于第0周的数值为88.7%。换言之,在连续服用4周的含有副干酪乳杆菌TCI708 的活菌胶囊后,7位受试者的肌肤松弛度下降11.3%。
请参阅图6。将7位受试者于第0周测试到的皱纹的平均数值视为 100%,且7位受试者于第4周测试到的皱纹的平均数值相较于第0周的数值为95.1%。换言之,在连续服用4周的含有副干酪乳杆菌TCI708的活菌胶囊后,7位受试者的皱纹下降4.9%。
请参阅图7及图8。在第0周时,受试者眼下的皱纹WK-0较深且多,如图7所示。在第4周时,受试者眼下的皱纹WK-4较浅且稀疏,如图8所示。于此,相较于第0周时的皱纹状态,在连续服用4周的含有副干酪乳杆菌TCI708的活菌胶囊后,受试者的皱纹减少。由此可知,副干酪乳杆菌 TCI708具有改善皱纹的能力。
于此,通过实验二可知,副干酪乳杆菌TCI708可适应于人体肠胃环境。通过实验三可知,副干酪乳杆菌TCI708具有去除醣化终产物的能力。并且,通过实验四可知,在服用副干酪乳杆菌TCI708后,可有效降低人体内醣化终产物的累积,从而改善受体肌肤状态,如提高肌肤明亮度、减少肌肤松弛度及/或改善皱纹。
综上所述,根据本发明任一实施例的副干酪乳杆菌TCI708,其可制备去除醣化终产物的组合物。并且,副干酪乳杆菌TCI708具有耐胃酸胆盐的功能,可生存于肠胃道环境。由于副干酪乳杆菌TCI708可用以去除醣化终产物,其有效降低人体内累积的醣化终产物,从而改善人体肌肤状态(如,肌肤明亮度、肌肤松弛度及皱纹)。
虽然本发明以前述的实施例揭露如上,然其并非用以限定本发明,任何熟习相像技术者,在不脱离本发明的精神和范围内,当可作些许的更动与润饰,因此本发明的专利保护范围须视本说明书所附的权利要求书所界定者为准。
序列表
<110> 大江生医
<120> 副干酪乳杆菌及副干酪乳杆菌用于制备去除醣化终产物的组合物的用途
<130> 929-1150.20P1
<160> 2
<170> SIPOSequenceListing 1.0
<210> 1
<211> 1064
<212> DNA
<213> Lactobacillus paracasei TCI708
<400> 1
gggtgttggc tacaatcgta tacatgcaag tcgaacgagt tctcgttgat gatcggtgct 60
tgcaccgaga ttcaacatgg aacgagtggc ggacgggtga gtaacacgtg ggtaacctgc 120
ccttaagggg ggataacatt tggaaacaga tgctaatacc gcatagatcc aagaaccgca 180
tggttcttgg ctgaaagatg gcgtaagcta tcgcttttgg atggacccgc ggcgtattag 240
ctagttggtg aggtatggct caccaaggcg atgatacgta gccgaactga gaggttgatc 300
ggccacattg ggactgagac acggcccaaa ctcctacggg aggcagcagt agggaatctt 360
ccacaatgga cgcaagtctg aggagcaacg ccgcgtgagt gaagaaggct ttcgggtcgt 420
aaaactctgt tgttggagaa gaatggtcgg cagagtaact gttgtcggcg tgacggtatc 480
caaccagaaa gccacggcta actacgtgca gcagccgcgg taatacgtag gtggcaagcg 540
ttatccggat ttattgggcg taaagcgagc gcaggcggtt ttttaagtct gatgtgaaag 600
ccctcggctt aaccgaggaa gcgcatcgga aactggaaac ttgagtgcag aagaggacag 660
tggaactcca tgtgtagcgg tgaaatgcgt agatatatgg aagaacacca gtggcgaagg 720
cggctgtctg gtctgtaact gacgctgagg ctcgaaagca tggtagcgaa caggattaga 780
taccctggta gtccatgccg taaacgatga atgctaggtg ttggagagtt tccgcccttc 840
agtgccgcag ctaacgcatt aagcattccg cctggggagt acgaccgcag gttgaaactc 900
aaaggaattg acgggggccc gcacaagcgg tggagcatgt ggtttaattc gaagcacgcg 960
aagaacctta ccagtcttga catctttttg atcactgaga gatcagcttc cccttcgggc 1020
aaatgacagt gtgcatgatg tcgtcagctc tggtcctgaa atgt 1064
<210> 2
<211> 1155
<212> DNA
<213> Lactobacillus paracasei L1044
<400> 2
cggcgatggg cggcgtgcct aatacatgca agtcgaacga gttctcgttg atgatcggtg 60
cttgcaccga gattcaacat ggaacgagtg gcggacgggt gagtaacacg tgggtaacct 120
gcccttaagt gggggataac atttggaaac agatgctaat accgcataga tccaagaacc 180
gcatggttct tggctgaaag atggcgtaag ctatcgcttt tggatggacc cgcggcgtat 240
tagctagttg gtgaggtaat ggctcaccaa ggcgatgata cgtagccgaa ctgagaggtt 300
gatcggccac attgggactg agacacggcc caaactccta cgggaggcag cagtagggaa 360
tcttccacaa tggacgcaag tctgatggag caacgccgcg tgagtgaaga aggctttcgg 420
gtcgtaaaac tctgttgttg gagaagaatg gtcggcagag taactgttgt cggcgtgacg 480
gtatccaacc agaaagccac ggctaactac gtgccagcag ccgcggtaat acgtaggtgg 540
caagcgttat ccggatttat tgggcgtaaa gcgagcgcag gcggtttttt aagtctgatg 600
tgaaagccct cggcttaacc gaggaagcgc atcggaaact gggaaacttg agtgcagaag 660
aggacagtgg aactccatgt gtagcggtga aatgcgtaga tatatggaag aacaccagtg 720
gcgaaggcgg ctgtctggtc tgtaactgac gctgaggctc gaaagcatgg gtagcgaaca 780
ggattagata ccctggtagt ccatgccgta aacgatgaat gctaggtgtt ggagggtttc 840
cgcccttcag tgccgcagct aacgcattaa gcattccgcc tggggagtac gaccgcaagg 900
ttgaaactca aaggaattga cgggggcccg cacaagcggt ggagcatgtg gtttaattcg 960
aagcaacgcg aagaacctta ccaggtcttg acatcttttg atcacctgag agatcagttt 1020
cccctttcgg gggcaaaatg acagtggtgc atgtgtcgtc agctcgtgtc gtgagatgtg 1080
ggtaagtccc gcacgagcgc aacccttatg actagttgcc aggcatttag ttgggcacct 1140
cttagtaaga actgc 1155
Claims (9)
1.一种副干酪乳杆菌TCI708(Lactobacillus paracasei TCI708),其中副干酪乳杆菌TCI708保藏于DSMZ德国微生物保藏中心保藏(German Collection of Microorganismsand Cell Cultures,DSMZ),保藏号为:DSM33482。
2.如权利要求1所述的副干酪乳杆菌TCI708,其特征在于,该副干酪乳杆菌TCI708具有耐胃酸胆盐的功能。
3.如权利要求2所述的副干酪乳杆菌TCI708,其特征在于,该副干酪乳杆菌TCI708于胃模拟环境的存活率为95%。
4.如权利要求2所述的副干酪乳杆菌TCI708,其特征在于,该副干酪乳杆菌TCI708于肠道模拟环境的存活率为99%。
5.如权利要求1所述的副干酪乳杆菌TCI708,其特征在于,该副干酪乳杆菌TCI708用以去除醣化终产物(Advanced Glycation End Products,AGEs)。
6.一种副干酪乳杆菌TCI708用于制备去除醣化终产物的组合物的用途,其中副干酪乳杆菌TCI708保藏于DSMZ德国微生物保藏中心保藏(German Collection ofMicroorganisms and Cell Cultures,DSMZ),保藏号为:DSM33482。
7.如权利要求6所述的用途,其特征在于,该副干酪乳杆菌TCI708具有耐胃酸胆盐的功能。
8.如权利要求6所述的用途,其特征在于,该副干酪乳杆菌TCI708具有改善肌肤状态的功能。
9.如权利要求6所述的用途,其特征在于,其中组合物为一医药组合物或一食品组合物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962875997P | 2019-07-19 | 2019-07-19 | |
US62/875,997 | 2019-07-19 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112239732A true CN112239732A (zh) | 2021-01-19 |
CN112239732B CN112239732B (zh) | 2022-07-22 |
Family
ID=74170548
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010695387.2A Active CN112239732B (zh) | 2019-07-19 | 2020-07-17 | 副干酪乳杆菌及副干酪乳杆菌用于制备去除糖化终产物的组合物的用途 |
CN202010692219.8A Pending CN112237590A (zh) | 2019-07-19 | 2020-07-17 | 台湾藜汁液及其用途以及减脂组合物 |
CN202010702882.1A Active CN112239733B (zh) | 2019-07-19 | 2020-07-20 | 特氏盐芽抱杆菌tci66207菌株及其破菌液及破菌液的用途 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010692219.8A Pending CN112237590A (zh) | 2019-07-19 | 2020-07-17 | 台湾藜汁液及其用途以及减脂组合物 |
CN202010702882.1A Active CN112239733B (zh) | 2019-07-19 | 2020-07-20 | 特氏盐芽抱杆菌tci66207菌株及其破菌液及破菌液的用途 |
Country Status (3)
Country | Link |
---|---|
US (2) | US11712413B2 (zh) |
CN (3) | CN112239732B (zh) |
TW (4) | TWI754327B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115992063B (zh) * | 2022-08-29 | 2023-08-18 | 甘肃省科学院生物研究所 | 一种抗盐碱复合微生物菌剂、制备方法及应用 |
CN117511768B (zh) * | 2023-10-07 | 2024-06-28 | 农业农村部成都沼气科学研究所 | 一种耐盐促生透明纤细芽孢杆菌及其应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101869740B1 (ko) * | 2017-06-23 | 2018-06-21 | 한국식품연구원 | 최종당화산물 저감 활성을 갖는 신규한 락토바실러스 파라카제이 균주 및 이의 용도 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2265249B1 (en) | 2008-04-15 | 2018-08-29 | Lucas Meyer Cosmetics Canada Inc. | Cosmetic compositions comprising exopolysaccharides derived from microbial mats, and use thereof |
TWI426915B (zh) * | 2010-12-29 | 2014-02-21 | Univ Nat Pingtung Sci & Tech | 台灣藜用以製備治療高血脂症及高膽固醇症之藥物的用途及其醫藥組成物 |
CN103468612B (zh) * | 2013-09-05 | 2016-09-14 | 大连交通大学 | 中度嗜盐菌株及由该菌株产生的嗜盐酯酶及其应用 |
TWI516280B (zh) * | 2014-03-20 | 2016-01-11 | 大江生醫股份有限公司 | 紅藜萃取物用於製備促進膠原蛋白生成及抗皮膚老化之組合物之用途 |
CN205700946U (zh) * | 2016-03-01 | 2016-11-23 | 常春藤生技股份有限公司 | 一种加工不易形成体脂肪的台湾红藜的设备 |
US20200270709A1 (en) * | 2017-04-06 | 2020-08-27 | Korea Food Research Institute | Novel Strain Having Activity Of Reducing Advanced Glycation End Products And Use Thereof |
TWI691340B (zh) * | 2017-05-11 | 2020-04-21 | 嘉藥學校財團法人嘉南藥理大學 | 一種具抗老化、美白、抗過敏及細胞修護之紅藜萃取物 |
TW201912177A (zh) * | 2017-08-23 | 2019-04-01 | 宋祖瑩 | 具美白與抗老功能的臺灣藜殼萃取區分物及其萃取與分離方法 |
CN108641982B (zh) * | 2018-05-09 | 2020-07-03 | 青海省农林科学院 | 一种特氏盐芽孢杆菌s61及其应用 |
-
2020
- 2020-07-17 TW TW109124354A patent/TWI754327B/zh active
- 2020-07-17 TW TW112134410A patent/TW202400125A/zh unknown
- 2020-07-17 CN CN202010695387.2A patent/CN112239732B/zh active Active
- 2020-07-17 TW TW109124353A patent/TWI820342B/zh active
- 2020-07-17 CN CN202010692219.8A patent/CN112237590A/zh active Pending
- 2020-07-20 TW TW109124488A patent/TWI801746B/zh active
- 2020-07-20 CN CN202010702882.1A patent/CN112239733B/zh active Active
- 2020-07-20 US US16/932,867 patent/US11712413B2/en active Active
-
2023
- 2023-06-14 US US18/334,392 patent/US20230414487A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101869740B1 (ko) * | 2017-06-23 | 2018-06-21 | 한국식품연구원 | 최종당화산물 저감 활성을 갖는 신규한 락토바실러스 파라카제이 균주 및 이의 용도 |
Also Published As
Publication number | Publication date |
---|---|
US20230414487A1 (en) | 2023-12-28 |
CN112239732B (zh) | 2022-07-22 |
TW202103680A (zh) | 2021-02-01 |
TWI801746B (zh) | 2023-05-11 |
CN112239733A (zh) | 2021-01-19 |
TWI820342B (zh) | 2023-11-01 |
US20210015736A1 (en) | 2021-01-21 |
TW202103716A (zh) | 2021-02-01 |
US11712413B2 (en) | 2023-08-01 |
TW202103683A (zh) | 2021-02-01 |
TW202400125A (zh) | 2024-01-01 |
CN112237590A (zh) | 2021-01-19 |
TWI754327B (zh) | 2022-02-01 |
CN112239733B (zh) | 2022-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
de Melo Pereira et al. | How to select a probiotic? A review and update of methods and criteria | |
EP2823822B1 (en) | A Bifidobacterium strain | |
Panigrahi et al. | Immune responses in rainbow trout Oncorhynchus mykiss induced by a potential probiotic bacteria Lactobacillus rhamnosus JCM 1136 | |
KR102372949B1 (ko) | 부티르산 산생균 및 그 이용 | |
Heravi et al. | Screening of lactobacilli bacteria isolated from gastrointestinal tract of broiler chickens for their use as probiotic | |
KR102091175B1 (ko) | 장내 항염증 및 균총 개선 활성을 갖는 락토바실러스 람노서스 균주 | |
CN110564638A (zh) | 一株具有益生特性的罗伊氏乳杆菌及其用途 | |
CN1819771A (zh) | 包含至少两种能定居在胃肠道中以及具有肠存活特性,肠结合特性,感染保护特性和纤维发酵特性的乳酸菌株的益生菌组合物 | |
CN112239732B (zh) | 副干酪乳杆菌及副干酪乳杆菌用于制备去除糖化终产物的组合物的用途 | |
US9259019B2 (en) | Bifidobacteriumstrain | |
Saman et al. | Evaluation of prebiotic property in edible mushrooms | |
Xu et al. | Lactobacillus casei JY300-8 generated by 12C6+ beams mutagenesis inhibits tumor progression by modulating the gut microbiota in mice | |
JP5610472B2 (ja) | 新規乳酸菌及び新規乳酸菌含有組成物 | |
CN105505815A (zh) | 一株抗衰老功能的粘膜乳杆菌 | |
Divisekera et al. | Isolation and identification of lactic acid bacteria with probiotic potential from fermented flour of selected banana varieties grown in Sri Lanka | |
CN114533768B (zh) | 乳酸杆菌益生菌CGMCC No.1.13855在制备糖尿病治疗药物中的应用 | |
EP3793580A1 (en) | Probiotic strain lactobacillus kefiri sgl 13 and use thereof for the prevention and treatment of intestinal inflammation and in the prevention of intestinal neoplasms | |
CN114456969A (zh) | 一种用于减肥降血糖的益生菌制剂及其制备方法和应用 | |
Lavanya et al. | Isolation and characterization of probiotic bacteria from the soil samples of the coastal areas of (Gudur division, Nellore Dt.) for utilization in Shrimp farming | |
JP2022130286A (ja) | 菌叢を改善するための組成物、およびそれを用いた菌叢を改善するための方法、並びにその応用 | |
Akther et al. | Optimizing the fermentation condition of low salted squid jeotgal by lactic acid bacteria with enhanced antioxidant activity | |
Kim et al. | In vitro characterization study of Bacillus mojavensis KJS-3 for a potential probiotic | |
KR102488609B1 (ko) | 장내 유해세균 억제 기능을 가진 락토바실러스 파라부크네리 nsmj16 (kacc81129bp) 및 락토바실러스 브레비스 nsmj23(kacc81130bp) | |
EP4375365A1 (en) | Novel lactobacillus paracasei atg-e1 strain or composition comprising same for preventing or treating respiratory disease | |
JP6995411B2 (ja) | 新規ビフィドバクテリウム属細菌及びそれを含む組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |